Beyond weight loss: the emerging role of incretin-based treatments in cardiometabolic HFpEF

Item Type:	Review
Title:	Beyond weight loss: the emerging role of incretin-based treatments in cardiometabolic HFpEF
Creators Name:	Capone, F. and Nambiar, N. and Schiattarella, G.G.
Abstract:	PURPOSE OF REVIEW: Incretin-based drugs are potent weight-lowering agents, emerging as potential breakthrough therapy for the treatment of obesity-related phenotype of heart failure with preserved ejection fraction (HFpEF). In this review article, we will discuss the contribution of weight loss as part of the benefits of incretin-based medications in obese patients with HFpEF. Furthermore, we will describe the potential effects of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists on the heart, particularly in relation to HFpEF pathophysiology. RECENT FINDINGS: In the STEP-HFpEF trial, the GLP-1 receptor agonist semaglutide significantly improved quality of life outcomes in obese HFpEF patients. Whether the beneficial effects of semaglutide in obese patients with HFpEF are merely a consequence of body weight reduction is unclear. Considering the availability of other weight loss strategies (e.g., caloric restriction, exercise training, bariatric surgery) to be used in obese HFpEF patients, answering this question is crucial to provide tailored therapeutic options in these subjects. SUMMARY: Incretin-based drugs may represent a milestone in the treatment of obesity in HFpEF. Elucidating the contribution of weight loss in the overall benefit observed with these drugs is critical in the management of obese HFpEF patients, considering that other weight-lowering strategies are available and might represent potential alternative options for these patients.
Keywords:	Glucagon-Like Peptide 1, Heart Failure, Incretins, Obesity, Quality of Life, Stroke Volume, Type 2 Diabetes Mellitus, Weight Loss
Source:	Current Opinion in Cardiology
ISSN:	0268-4705
Publisher:	Lippincott Williams & Wilkins
Volume:	39
Number:	2
Page Range:	148-153
Date:	May 2024
Official Publication:	https://doi.org/10.1097/HCO.0000000000001117
PubMed:	View item in PubMed

Repository Staff Only: item control page